JP2014516538A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516538A5 JP2014516538A5 JP2014512143A JP2014512143A JP2014516538A5 JP 2014516538 A5 JP2014516538 A5 JP 2014516538A5 JP 2014512143 A JP2014512143 A JP 2014512143A JP 2014512143 A JP2014512143 A JP 2014512143A JP 2014516538 A5 JP2014516538 A5 JP 2014516538A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- cells
- patient
- full
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 71
- 239000000427 antigen Substances 0.000 claims description 68
- 108091007433 antigens Proteins 0.000 claims description 67
- 102000036639 antigens Human genes 0.000 claims description 67
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 15
- 238000012258 culturing Methods 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000024932 T cell mediated immunity Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000028996 humoral immune response Effects 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000013610 patient sample Substances 0.000 claims description 3
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 6
- 230000030741 antigen processing and presentation Effects 0.000 claims 5
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 230000000638 stimulation Effects 0.000 claims 3
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 108010002586 Interleukin-7 Proteins 0.000 claims 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 238000012737 microarray-based gene expression Methods 0.000 claims 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- 229960002930 sirolimus Drugs 0.000 claims 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 101150113776 LMP1 gene Proteins 0.000 claims 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims 1
- 102000003425 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490505P | 2011-05-26 | 2011-05-26 | |
| US61/490,505 | 2011-05-26 | ||
| PCT/US2012/039605 WO2012162620A1 (en) | 2011-05-26 | 2012-05-25 | Modulated immunodominance therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014516538A JP2014516538A (ja) | 2014-07-17 |
| JP2014516538A5 true JP2014516538A5 (cg-RX-API-DMAC7.html) | 2015-07-02 |
Family
ID=46208182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014512143A Pending JP2014516538A (ja) | 2011-05-26 | 2012-05-25 | 調節された免疫優勢療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US20140099341A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2714072A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014516538A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20160104753A (cg-RX-API-DMAC7.html) |
| CN (2) | CN103906531A (cg-RX-API-DMAC7.html) |
| AU (4) | AU2012258603A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2874431A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1199404A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2013157923A (cg-RX-API-DMAC7.html) |
| SG (2) | SG10201604236RA (cg-RX-API-DMAC7.html) |
| TW (3) | TWI774957B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012162620A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190030661A (ko) * | 2016-05-25 | 2019-03-22 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 동종이계 t 세포를 이용한 자가면역 질환을 치료하는 방법 |
| NZ749136A (en) | 2016-05-25 | 2023-11-24 | Council Queensland Inst Medical Res | Methods of immunotherapy |
| AU2017283480A1 (en) | 2016-06-13 | 2019-01-24 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| JP7034955B2 (ja) * | 2016-06-28 | 2022-03-14 | ジーニアス・バイオテクノロジー・インコーポレイテッド | 免疫療法向けのｔ細胞組成物 |
| EP3678701A4 (en) | 2017-09-05 | 2021-12-01 | Torque Therapeutics, Inc. | THERAPEUTIC PROTEIN COMPOSITIONS AND METHODS FOR PREPARING AND USING THE SAME |
| EP3700553A1 (en) | 2017-10-23 | 2020-09-02 | Atara Biotherapeutics, Inc. | Methods of managing tumor flare in adoptive immunotherapy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE511849T1 (de) | 1996-03-11 | 2011-06-15 | Epimmune Inc | Peptide mit erhöhter bindungsaffinität für mindestens drei hla-a3-ähnliche moleküle |
| JP2001509677A (ja) * | 1997-01-31 | 2001-07-24 | エピミューン，インコーポレイティド | Ｃｔｌを活性化するためのペプチドおよびペプチド担持抗原提示細胞 |
| DE69941150D1 (de) | 1998-05-11 | 2009-09-03 | Miltenyi Biotec Gmbh | Verfahren zur direkten auswahl von antigen-spezifischen t-zellen |
| JP2002526419A (ja) * | 1998-10-05 | 2002-08-20 | ファーメクサ エイ／エス | 治療上のワクチン注射のための新規な方法 |
| NZ521715A (en) * | 2000-04-28 | 2008-01-31 | Mannkind Corp | Method of identifying and producing antigen peptides and use thereof as vaccines |
| FR2812087B1 (fr) * | 2000-07-21 | 2007-05-11 | Inst Nat Sante Rech Med | Procede de criblage de peptides utilisables en immunotherapie |
| JP2006505259A (ja) | 2002-11-07 | 2006-02-16 | ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド | 疾患特異的細胞傷害性ｔリンパ球の集団を産生および利用する手段 |
| ES2350895T3 (es) * | 2004-08-19 | 2011-01-28 | University College Cardiff Consultants Limited | Preparación de células t gamma delta humanas presentadoras de antígeno y su uso en inmunoterapia. |
| JP2008526763A (ja) * | 2004-12-29 | 2008-07-24 | マンカインド コーポレイション | 予防又は治療目的のｍｈｃクラスｉ拘束性エピトープに対する免疫応答の誘導、増強及び保持方法 |
| EP2385059A3 (en) * | 2005-06-17 | 2012-02-15 | Mannkind Corporation | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
| ES2953434T3 (es) | 2009-08-24 | 2023-11-13 | Baylor College Medicine | Generación de líneas de CTL con especificidad frente a múltiples antígenos tumorales o múltiples virus |
-
2012
- 2012-05-25 SG SG10201604236RA patent/SG10201604236RA/en unknown
- 2012-05-25 US US14/122,036 patent/US20140099341A1/en not_active Abandoned
- 2012-05-25 WO PCT/US2012/039605 patent/WO2012162620A1/en not_active Ceased
- 2012-05-25 RU RU2013157923/10A patent/RU2013157923A/ru not_active Application Discontinuation
- 2012-05-25 SG SG10202012534VA patent/SG10202012534VA/en unknown
- 2012-05-25 CA CA2874431A patent/CA2874431A1/en active Pending
- 2012-05-25 KR KR1020167023641A patent/KR20160104753A/ko not_active Ceased
- 2012-05-25 HK HK14113011.2A patent/HK1199404A1/xx unknown
- 2012-05-25 JP JP2014512143A patent/JP2014516538A/ja active Pending
- 2012-05-25 EP EP12725589.1A patent/EP2714072A1/en not_active Withdrawn
- 2012-05-25 CN CN201280037470.4A patent/CN103906531A/zh active Pending
- 2012-05-25 EP EP23158828.6A patent/EP4285922A1/en active Pending
- 2012-05-25 AU AU2012258603A patent/AU2012258603A1/en not_active Abandoned
- 2012-05-25 CN CN201911266293.7A patent/CN111529697A/zh active Pending
- 2012-05-25 KR KR1020137034616A patent/KR20140068810A/ko not_active Ceased
- 2012-05-28 TW TW108117367A patent/TWI774957B/zh active
- 2012-05-28 TW TW101118979A patent/TW201313902A/zh unknown
- 2012-05-28 TW TW111127515A patent/TW202321442A/zh unknown
-
2016
- 2016-10-28 US US15/337,620 patent/US20170043000A1/en not_active Abandoned
- 2016-10-28 US US15/337,415 patent/US20170042998A1/en not_active Abandoned
- 2016-10-28 US US15/337,661 patent/US20170043001A1/en not_active Abandoned
- 2016-10-28 US US15/337,506 patent/US20170042999A1/en not_active Abandoned
- 2016-10-28 US US15/337,556 patent/US20170101625A1/en not_active Abandoned
-
2017
- 2017-04-13 US US15/486,864 patent/US11723921B2/en active Active
- 2017-05-31 AU AU2017203671A patent/AU2017203671A1/en not_active Abandoned
-
2019
- 2019-03-01 AU AU2019201456A patent/AU2019201456A1/en not_active Abandoned
-
2021
- 2021-02-10 AU AU2021200831A patent/AU2021200831A1/en not_active Abandoned
-
2023
- 2023-06-28 US US18/343,693 patent/US20240189353A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abbott et al. | Cancer and the immune system: the history and background of immunotherapy | |
| Su et al. | Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models | |
| Maue et al. | An ESAT-6: CFP10 DNA vaccine administered in conjunction with Mycobacterium bovis BCG confers protection to cattle challenged with virulent M. bovis | |
| JP2014516538A5 (cg-RX-API-DMAC7.html) | ||
| JP2005523277A (ja) | 癌の治療 | |
| Tian et al. | Luteolin as an adjuvant effectively enhances CTL anti-tumor response in B16F10 mouse model | |
| Lim et al. | DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors | |
| Bhattacharyya et al. | Immunological interactions in radiotherapy—opening a new window of opportunity | |
| Toubaji et al. | The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection | |
| Becker et al. | Skin vaccination with live virus vectored microneedle arrays induce long lived CD8+ T cell memory | |
| Freitas-Silva et al. | Dendritic cell-based approaches in the fight against diseases | |
| JP2018016651A (ja) | 能動免疫療法のためのＴｈ１ワクチン接種プライミング | |
| Lu et al. | Chrysin enhances antitumour immunity response through the IL‐12‐STAT4 signal pathway in the B16F10 melanoma mouse model | |
| Grasse et al. | GM-CSF improves the immune response to the diphtheria-component in a multivalent vaccine | |
| Brody et al. | Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors | |
| Dai et al. | Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice | |
| RU2013157923A (ru) | Терапия на основе модулирования иммунодоминантности | |
| US20110319871A1 (en) | Infectious disease cellular immunotherapy | |
| EP1793678A1 (en) | Dendritic cell tumor injection (dcti) therapy | |
| Pawelec et al. | Impact of aging on cancer immunity and immunotherapy | |
| Jin et al. | The Epitope Basis of Embryonic Stem Cell‐Induced Antitumor Immunity against Bladder Cancer | |
| Riemann et al. | Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART‐1 | |
| Locy et al. | Dendritic cells: the tools for cancer treatment | |
| Zhang et al. | Enhancement of antitumor immunity using a DNA-based replicon vaccine derived from Semliki Forest virus | |
| Smyth et al. | Repetitive peptide boosting progressively enhances functional memory CTLs |